Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABBV 
AbbVie Inc (ABBV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ABBV (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $215.7
1 Year Target Price $215.7
| 12 | Strong Buy |
| 4 | Buy |
| 12 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.13% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 367.55B USD | Price to earnings Ratio 99.08 | 1Y Target Price 215.7 |
Price to earnings Ratio 99.08 | 1Y Target Price 215.7 | ||
Volume (30-day avg) 28 | Beta 0.5 | 52 Weeks Range 159.42 - 214.80 | Updated Date 08/28/2025 |
52 Weeks Range 159.42 - 214.80 | Updated Date 08/28/2025 | ||
Dividends yield (FY) 3.11% | Basic EPS (TTM) 2.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.45% | Operating Margin (TTM) 37.52% |
Management Effectiveness
Return on Assets (TTM) 8.87% | Return on Equity (TTM) 112.85% |
Valuation
Trailing PE 99.08 | Forward PE 17.39 | Enterprise Value 431564110119 | Price to Sales(TTM) 6.3 |
Enterprise Value 431564110119 | Price to Sales(TTM) 6.3 | ||
Enterprise Value to Revenue 7.4 | Enterprise Value to EBITDA 30.47 | Shares Outstanding 1766560000 | Shares Floating 1762954474 |
Shares Outstanding 1766560000 | Shares Floating 1762954474 | ||
Percent Insiders 0.1 | Percent Institutions 74.58 |
Upturn AI SWOT
AbbVie Inc
Company Overview
History and Background
AbbVie Inc. was founded in 2013 as a spin-off from Abbott Laboratories. It focuses on research, development, manufacturing, and commercialization of pharmaceuticals.
Core Business Areas
- Immunology: Focuses on treatments for autoimmune diseases like rheumatoid arthritis, psoriasis, and Crohn's disease. Key product: Humira (now biosimilars are available) and Skyrizi.
- Oncology: Develops treatments for various types of cancer. Key products: Imbruvica and Venclexta.
- Neuroscience: Focuses on treatments for neurological disorders, including migraine and Parkinson's disease. Key products: Botox Therapeutic and Ubrelvy.
- Aesthetics: Provides aesthetic products, including Botox Cosmetic and Juvederm dermal fillers.
Leadership and Structure
Richard A. Gonzalez serves as the Chairman and CEO. The company has a typical hierarchical structure with various departments reporting to executive leadership.
Top Products and Market Share
Key Offerings
- Skyrizi: A biologic used to treat psoriasis, psoriatic arthritis, and Crohn's disease. Skyrizi is expected to replace some of Humira's lost revenue due to biosimilars. Competitors: Stelara (Johnson & Johnson), Taltz (Eli Lilly).
- Imbruvica: A drug used to treat certain blood cancers like chronic lymphocytic leukemia (CLL). Competitors: Calquence (AstraZeneca), Brukinsa (BeiGene).
- Botox Therapeutic: Used to treat various neurological conditions such as migraine and muscle spasms. Competitors: Xeomin (Merz), Dysport (Ipsen).
- Venclexta: A drug used to treat chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Competitors: Gazyva (Roche).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulations, and significant competition. Key trends include personalized medicine, biosimilars, and digital health.
Positioning
AbbVie Inc. is a major player in the pharmaceutical industry, particularly in immunology and oncology. Its competitive advantages include a strong product portfolio, robust R&D capabilities, and effective marketing strategies.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be over $1.4 trillion. AbbVie is positioned well to capture a significant portion of this TAM, but biosimilar competition presents a challenge.
Upturn SWOT Analysis
Strengths
- Strong product portfolio
- Robust R&D pipeline
- Established global presence
- High profit margins
- Experienced management team
Weaknesses
- Reliance on key products (Humira)
- Exposure to biosimilar competition
- High debt levels (related to acquisitions)
- Pipeline risk
- Dependence on FDA Approval.
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Growth in emerging markets
- Development of innovative therapies
- Increased demand for specialty pharmaceuticals
Threats
- Biosimilar competition (Humira)
- Patent expirations
- Pricing pressures
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- NVS
- LLY
Competitive Landscape
AbbVie faces intense competition from other large pharmaceutical companies. Its advantages include a strong immunology franchise and a robust pipeline. Its disadvantages include reliance on key products facing biosimilar competition.
Major Acquisitions
Allergan
- Year: 2020
- Acquisition Price (USD millions): 63000
- Strategic Rationale: Diversified AbbVie's product portfolio and reduced its reliance on Humira. Expanded into aesthetics and women's health.
Growth Trajectory and Initiatives
Historical Growth: AbbVie's historical growth has been driven by key products such as Humira and strategic acquisitions. Growth has slowed with Humira biosimilars.
Future Projections: Analyst estimates vary, but project continued growth driven by Skyrizi, Rinvoq, and other pipeline products. However, biosimilar erosion will remain a concern.
Recent Initiatives: Recent initiatives include focusing on next-generation products, expanding into new therapeutic areas, and pursuing strategic acquisitions.
Summary
AbbVie is a major pharmaceutical company with a strong presence in immunology and oncology. The company's key challenge is mitigating the impact of Humira biosimilars. Growth is expected to be driven by new products and strategic acquisitions, but high debt from past acquisitions will continue to be a concern. AbbVie needs to succesfully launch and grow its pipeline products to offset Humira's decline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- AbbVie Investor Relations
- SEC Filings
- Analyst Reports
- Industry Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AbbVie Inc
Exchange NYSE | Headquaters North Chicago, IL, United States | ||
IPO Launch date 2013-01-02 | CEO & Chairman of the Board Mr. Robert A. Michael CPA | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 55000 | Website https://www.abbvie.com |
Full time employees 55000 | Website https://www.abbvie.com | ||
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.